Johnson & Johnson (NYSE:JNJ) Stock Sold by Rep. Thomas H. Kean, Jr.

Representative Thomas H. Kean, Jr. (Republican-New Jersey) recently sold shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on November 19th, the Representative disclosed that they had sold between $1,001 and $15,000 in Johnson & Johnson stock on October 27th. The trade occurred in the Representative’s “STATE STREET BANK & TRUST CO.” account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

  • Sold $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 10/27/2026.
  • Sold $1,001 – $15,000 in shares of Stryker (NYSE:SYK) on 10/27/2026.
  • Sold $1,001 – $15,000 in shares of Warner Bros. Discovery (NASDAQ:WBD) on 10/7/2026.
  • Sold $1,001 – $15,000 in shares of Stryker (NYSE:SYK) on 9/30/2026.
  • Sold $1,001 – $15,000 in shares of Johnson & Johnson (NYSE:JNJ) on 9/30/2026.
  • Purchased $1,001 – $15,000 in shares of ESAB (NYSE:ESAB) on 9/29/2026.
  • Sold $1,001 – $15,000 in shares of Mondelez International (NASDAQ:MDLZ) on 9/23/2026.
  • Sold $1,001 – $15,000 in shares of Abbott Laboratories (NYSE:ABT) on 9/17/2026.
  • Purchased $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 9/17/2026.
  • Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 8/27/2026.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $270.54 on Friday. Johnson & Johnson has a twelve month low of $199.90 and a twelve month high of $290.25. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. The company’s 50-day moving average price is $267.53 and its 200-day moving average price is $250.98. The company has a market cap of $651.27 billion, a PE ratio of 40.99, a price-to-earnings-growth ratio of 2.72 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.06. The firm had revenue of $25.40 billion during the quarter, compared to analysts’ expectations of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, equities research analysts forecast that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be issued a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson’s payout ratio is 81.21%.

Hedge Funds Weigh In On Johnson & Johnson

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Outlook Capital Management LLC bought a new stake in Johnson & Johnson during the 2nd quarter valued at $28,000. Navigoe LLC increased its position in shares of Johnson & Johnson by 60.4% during the third quarter. Navigoe LLC now owns 146 shares of the company’s stock valued at $38,000 after buying an additional 55 shares during the period. Matrix Trust Co increased its position in shares of Johnson & Johnson by 56.2% in the second quarter. Matrix Trust Co now owns 150 shares of the company’s stock worth $38,000 after purchasing an additional 54 shares during the last quarter. Montgomery Financial Services LLC bought a new stake in Johnson & Johnson in the second quarter worth $43,000. Finally, Hanseatic Management Services Inc. bought a new stake in shares of Johnson & Johnson in the 3rd quarter worth approximately $52,000. 69.55% of the stock is currently owned by institutional investors.

Key Headlines Impacting Johnson & Johnson

Here are a few of the latest headlines about JNJ:

  • Positive Sentiment: J&J announced the first U.S. commercial installation of its OTTAVA surgical robot at a Houston hospital, an early step in bringing the platform to market and expanding its surgical-technology business. Article
  • Positive Sentiment: The company submitted an FDA application to expand CAPLYTA’s use to bipolar I mania or mixed episodes, supported by two positive Phase 3 studies. Approval is not guaranteed, but another indication could broaden the drug’s growth potential. Article
  • Negative Sentiment: A Louisiana appeals court upheld a multimillion-dollar talc verdict and increased damages, reinforcing ongoing litigation exposure for J&J. Article

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Leerink Partners reduced their price objective on shares of Johnson & Johnson from $276.00 to $272.00 and set an “outperform” rating for the company in a research report on Wednesday, October 14th. Royal Bank Of Canada dropped their target price on shares of Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating for the company in a report on Wednesday, October 14th. TD Cowen restated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, October 20th. Morgan Stanley lowered their price objective on shares of Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating on the stock in a research note on Thursday, October 15th. Finally, UBS Group set a $270.00 price target on Johnson & Johnson in a report on Wednesday, October 14th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $276.54.

View Our Latest Research Report on JNJ

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Elizabeth Forminard sold 13,072 shares of the business’s stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $284.39, for a total transaction of $3,717,546.08. Following the transaction, the executive vice president owned 16,994 shares of the company’s stock, valued at approximately $4,832,923.66. The trade was a 43.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president directly owned 25,447 shares in the company, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their position. The SEC filing for this sale provides additional information. 0.16% of the stock is owned by company insiders.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey’s 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey’s 7th Congressional District. He declared candidacy for the 2026 election.

Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

About Johnson & Johnson

(Get Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Featured Articles

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.